SPRY2

Across TCGA pan-cancer cohorts, SPRY2 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of SPRY2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney chromophobe (KICH), where SPRY2 RNA is repressed in tumor relative to normal tissue. In most cancer types SPRY2 is over-expressed in tumor, although a few such as KICH and LUSC show the opposite, repressed pattern.

KICH, LUSC, and LUAD are the cancer types where SPRY2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SPRY2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KICH	All	III,IV	−2.607	<.001	10	view →
LUSC	All	All	−0.989	<.001	8	view →
LUAD	Female	II,III,IV	−0.900	<.001	8	view →
BLCA	All	All	−1.063	.001	7	view →
KIRP	All	II,III,IV	−0.837	<.001	7	view →
BRCA	All	III,IV	−2.610	<.001	6	view →
STAD	Male	II,III,IV	+1.218	<.001	6	view →
LIHC	Male	All	−0.840	<.001	5	view →
COAD	Female	All	+0.673	<.001	5	view →
KIRC	All	II,III,IV	−0.449	.004	3	view →
THCA	Female	All	−0.441	.006	3	view →
UCEC	All	All	−1.059	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

SPRY2–KICH

Open the KICH breakdown →